H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Phase 1

Completed

Conditions: Cytochrome P450 Interaction

Interventions: Drug: Lu AF35700
Drug: Itraconazole (200 mg)
Drug: Itraconazole (300 mg)

First Posted Date: 2017-04-06

Last Posted Date: 2019-10-02

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 22

Registration Number: NCT03103646

Locations: 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
🇺🇸
Covance - Dallas, Dallas, Texas, United States

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Other: Placebo (IV)
Drug: Vortioxetine (IV)
Drug: Vortioxetine (tablet)

First Posted Date: 2016-09-29

Last Posted Date: 2018-06-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 55

Registration Number: NCT02919501

Locations: 🇫🇮
FI1041, Helsinki, Finland
🇪🇪
EE1019, Tallinn, Estonia
🇫🇮
FI1040, Helsinki, Finland

and more 4 locations

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Phase 1

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Lu AF35700 (10 mg/day)
Drug: Lu AF35700 (30 mg/day)
Drug: Quetiapine (Seroquel XR® 800 mg/day)

First Posted Date: 2016-09-15

Last Posted Date: 2019-09-12

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 119

Registration Number: NCT02901587

Locations: 🇺🇸
US1104, Long Beach, California, United States

Bioequivalence Study of Idalopirdine in Healthy Subjects

Phase 1

Withdrawn

Conditions: Bioequivalence

Interventions: Drug: Idalopirdine commercial tablet (test)
Drug: Idalopirdine clinical tablet (reference)

First Posted Date: 2016-09-09

Last Posted Date: 2016-11-11

Lead Sponsor: H. Lundbeck A/S

Registration Number: NCT02894515

Locations: 🇬🇧
GB1050, Leeds, United Kingdom

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lu AF35700

First Posted Date: 2016-09-08

Last Posted Date: 2020-10-26

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 528

Registration Number: NCT02892422

Locations: 🇺🇸
US1244, Fresh Meadows, New York, United States
🇺🇸
US1404, Shreveport, Louisiana, United States
🇺🇸
US1190, Staten Island, New York, United States

and more 99 locations

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Phase 3

Terminated

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine

First Posted Date: 2016-08-18

Last Posted Date: 2022-12-28

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 662

Registration Number: NCT02871297

Locations: 🇿🇦
Cape Trial Centre, Bellville, Cape Town, South Africa
🇬🇧
NHS Greater Glasgow and Clyde Glasgow Clinical Research Facility-Queen Elizabeth University Hospi..., Glasgow, United Kingdom
🇪🇸
Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 75 locations

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Phase 3

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: brexpiprazole
Drug: risperidone

First Posted Date: 2016-05-02

Last Posted Date: 2016-08-01

Lead Sponsor: H. Lundbeck A/S

Registration Number: NCT02758067

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lu AF35700
Drug: Risperidone
Drug: Olanzapine

First Posted Date: 2016-03-23

Last Posted Date: 2019-11-25

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 1098

Registration Number: NCT02717195

Locations: 🇧🇬
BG1029, Veliko Tŭrnovo, Bulgaria
🇲🇽
MX1011, Guadalajara, Mexico
🇲🇽
MX1022, Guadalajara, Mexico

and more 144 locations

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine 10 mg/day
Drug: Vortioxetine 20 mg/day
Drug: Fluoxetine 20 mg/day
Other: Placebo

First Posted Date: 2016-03-16

Last Posted Date: 2020-08-19

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 784

Registration Number: NCT02709746

Locations: 🇺🇸
US1386, Wichita, Kansas, United States
🇨🇴
CO1004, Bogotá, Colombia
🇨🇴
CO1002, Pereira, Colombia

and more 121 locations

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine 10 mg/day
Drug: Vortioxetine 20 mg/day
Drug: Fluoxetine 20mg/day
Other: Placebo

First Posted Date: 2016-03-16

Last Posted Date: 2022-09-22

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 683

Registration Number: NCT02709655

Locations: 🇺🇸
Sun Valley Research Center, Imperial, California, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Northwest Behavioral Research Center, Marietta, Georgia, United States

and more 95 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy